Numerous mouse models that express altered APP or metabolite levels exhibit elevated rates of spontaneous or provoked seizures (Moechars et al., 1996; Steinbach et al., 1998; Del Vecchio et al., 2004; Lalonde et al., 2005; Palop et al., 2007; Kobayashi et al., 2008; Westmark et al., 2008; Minkeviciene et al., 2009; Ziyatdinova et al., 2011; Sanchez et al., 2012) while suppression of transgenic APP in Alzheimer's disease mice during postnatal development delays the onset of EEG abnormalities (Born et al., 2014). The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.